Webinar: How to build a leading-practice RWE program to inform Market Access and value-based drug contracting

Real-world evidence (RWE) is playing a growing role in drug value and market access decision-making. U.S. payers frequently expect RWE that demonstrates drug effectiveness in their member populations, while HTAs—globally and in the U.S., with ICER—are leveraging RWE for their value assessments.

In this webinar, experts from Aetion and industry explore emerging trends in the use of RWE to inform market access and innovative managed care contracting. The webinar will also cover examples of how biopharma manufacturers are using RWE to engage in value-based contracts with payers, and how to structure these programs for long-term success.